• United Therapeutics recently completed its Phase 3 TETON-1 trial of inhaled treprostinil in idiopathic pulmonary fibrosis, a double-blind, placebo-controlled 52-week study assessing whether the drug can slow lung function decline.
• This milestone, building on earlier TETON-2 findings, could be pivotal for expanding the Tyvaso franchise into IPF and informing potential regulatory filings.
• Next, we’ll examine how completing the TETON-1 Phase 3 IPF trial could reshape United Therapeutics’ long-term organ manufacturing and pulmonary growth narrative.

AI is about to change healthcare. These 24 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

United Therapeutics Investment Narrative Recap

To own United Therapeutics, you need to believe its PAH and pulmonary drugs can keep funding a high-risk push into IPF and organ technologies, despite growing competition and reimbursement pressure. Completing the Phase 3 TETON 1 IPF trial is a key near term catalyst because the eventual readout could significantly influence expectations for Tyvaso’s durability and pipeline value, while trial disappointment or delay remains one of the biggest current risks to the story.

Among recent announcements, the upcoming Q4 2025 earnings release on February 25 matters here, because it will frame how much financial flexibility United Therapeutics has to keep investing in IPF and organ manufacturing programs while managing competitive threats and any future TETON related outcomes.

Yet beneath the IPF opportunity, investors should be aware of how concentrated United Therapeutics remains in a handful of pulmonary drugs and...

United Therapeutics’ narrative projects $3.7 billion revenue and $1.5 billion earnings by 2028.

Uncover how United Therapeutics' forecasts yield a $530.84 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming revenue growth of only about 2.5 percent and earnings falling toward roughly US$962.0 million by 2028, so if you worry that future pulmonary fibrosis upside could be overestimated, TETON 1’s completion may eventually either reinforce that caution or meaningfully soften it, reminding you that views on United Therapeutics can differ sharply and are likely to evolve as new data arrives.

Explore 5 other fair value estimates on United Therapeutics - why the stock might be worth over 3x more than the current price!

Build Your Own United Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your United Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.